NASDAQ · TARA
Protara Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for TARA: Nov 9, 2026
Protara Therapeutics, Inc. Common Stock is estimated to report earnings on 11/09/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.37. The reported EPS for the same quarter last year was $-0.31.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.37 | $-0.36 | $-0.38 | 4 |
| Dec 2026 | $-0.38 | $-0.36 | $-0.41 | 4 |
| Mar 2027 | $-0.42 | $-0.38 | $-0.46 | 2 |
| Jun 2027 | $-0.44 | $-0.39 | $-0.49 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Zacks · Fintel- RTTNews · Aug 11, 2:34 PM EDTProtara Sets Multiple Clinical Catalysts For TARA-002; BLA Submission Targeted For 2H27(RTTNews) – Protara Therapeutics, Inc. (TARA), a clinical-stage biotechnology company focused on therapies for cancer and rare diseases, reported its second-quarter 2026 financial results and provided a business update, with investors focusing on progress across TARA-002, IV Chol
- Zacks · Jul 21, 12:00 PM EDTWhat Makes Protara Therapeutics (TARA) a New Buy StockProtara Therapeutics (TARA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- RTTNews · Jul 6, 8:40 AM EDTCorbus Pharmaceuticals Appoints Leonardo Viana Nicacio As CMO(RTTNews) – Corbus Pharmaceuticals Holdings, Inc. (CRBP), a company focused on oncology and obesity, said on Monday that it has appointed Leonardo Viana Nicacio as Chief Medical Officer.
- RTTNews · May 15, 7:48 AM EDTProtara Reports Positive Phase 2 Data For TARA-002 In Bladder Cancer Study(RTTNews) – Protara Therapeutics, Inc. (TARA) on Friday announced positive updated 12-month data from the Phase 2 ADVANCED-2 study evaluating TARA-002 in certain patients with non-muscle invasive bladder cancer (NMIBC).
- Fintel · Mar 4, 7:03 PM ESTJP Morgan Initiates Coverage of Protara Therapeutics (TARA) with Overweight RecommendationFintel reports that on March 4, 2026, JP Morgan initiated coverage of Protara Therapeutics (NasdaqGM:TARA) with a Overweight recommendation. Analyst Price Forecast Suggests 322.93% Upside
- RTTNews · Jan 9, 7:53 AM ESTWeekly Buzz: ScinoPharm Gets FDA Nod; GNLX's Olvi-Vec Shows Promise; GLUE's MRT-8102 Advances(RTTNews) – The biotech industry witnessed several key clinical trial data readouts across multiple therapeutic areas, including lung cancer, cardiovascular risk, Alzheimer's, and hepatitis.
- Fintel · Jan 7, 7:04 PM ESTPiper Sandler Initiates Coverage of Protara Therapeutics (TARA) with Overweight RecommendationFintel reports that on January 7, 2026, Piper Sandler initiated coverage of Protara Therapeutics (NasdaqGM:TARA) with a Overweight recommendation. Analyst Price Forecast Suggests 398.05% Upside
- RTTNews · Jan 7, 9:47 AM ESTProtara Doses First Patient In Phase 3 THRIVE-3 Trial Of IV Choline Chloride(RTTNews) – Protara Therapeutics, Inc. (TARA) has dosed the first patient in its pivotal Phase 3 registrational THRIVE-3 trial evaluating intravenous (IV) Choline Chloride in patients dependent on long-term parenteral support (PS).
- RTTNews · Dec 5, 8:57 AM ESTProtara Prices $75 Mln Offering To Advance TARA-002 And Broader Pipeline(RTTNews) – Shares of Protara Therapeutics Inc. (TARA) are down over 18% at $5.55 in premarket trading on Friday, after the company announced it has priced a $75 million underwritten public offering of 13 million shares of common stock at $5.75 per share.
- RTTNews · Dec 5, 7:10 AM ESTProtara Therapeutics Shares Sink 16% After $75 Mln Public Offering(RTTNews) – Shares of Protara Therapeutics Inc. (TARA) dropped about 16% in pre-market trading on Friday after the company announced the pricing of its underwritten public offering of about 13.04 million shares of common stock at $5.75 per share.
- Fintel · Dec 3, 7:05 PM ESTHC Wainwright & Co. Reiterates Protara Therapeutics (TARA) Buy RecommendationFintel reports that on December 3, 2025, HC Wainwright & Co. reiterated coverage of Protara Therapeutics (NasdaqGM:TARA) with a Buy recommendation. Analyst Price Forecast Suggests 309.97% Upside
- RTTNews · Dec 3, 9:49 AM ESTProtara Reports Updated Interim Phase 2 Data Of TARA-002 In Non-muscle Invasive Bladder Cancer(RTTNews) – Protara Therapeutics, Inc. (TARA) has reported new interim results from Cohort A of its ongoing Phase 2 ADVANCED-2 trial of TARA-002 in BCG- naïve patients with high-grade non-muscle invasive bladder cancer (NMIBC).
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Protara Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.